





## Genomic Health INC Rank 13 of 72

The relative strengths and weaknesses of Genomic Health INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Genomic Health INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 113% points. The greatest weakness of Genomic Health INC is the variable Selling and Marketing Expense, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 250%, being 86% points above the market average of 164%.

Input Variable	Value in 1000 USD
Assets, Current	130,209
Assets, Non-Current	9,421
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	47,064
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	25,340
Long Term Liabilities	0
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	45
Other Expenses	37,440
Other Liabilities	0
Other Net Income	237
Other Revenues	235,173
Property Plant and Equipment	14,104
Research And Development Expense	49,104
Selling and Marketing Expense	93,553

Output Variable	Value in 1000 USD
Assets	153,734
Liabilities	25,340
Expenses	227,161
Revenues	235,173
Stockholders Equity	128,394
Net Income	8,249
Comprehensive Net Income	8,294
BaseVar	320,845
ECR before LimitedLiability	217%
Economic Capital Ratio	250%